Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy

Share :
Published: 15 Jan 2024
Views: 56
Rating:
Save
Dr Michail Ignatiadis - Institut Jules Bordet, Brussels, Belgium

Dr Michail Ignatiadis provided an update on the ALEXANDRA/IMpassion030 phase 3 clinical trial in relation to cancer treatment.

The study aimed to investigate the efficacy, safety, and pharmacokinetic profile of adjuvant atezolizumab along with standard anthracycline/taxane chemotherapy when compared to chemotherapy alone in patients with early-stage triple-negative breast cancer.

The research concluded that the addition of atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer was found to be unlikely to improve efficacy.

Furthermore, the study also observed that with longer treatment exposure in the atezolizumab arm, adverse events were more frequent but consistent with the safety profile of atezolizumab.